| __timestamp | Merck & Co., Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 305409000 |
| Thursday, January 1, 2015 | 10313000000 | 377080000 |
| Friday, January 1, 2016 | 9762000000 | 432829000 |
| Sunday, January 1, 2017 | 9830000000 | 496079000 |
| Monday, January 1, 2018 | 10102000000 | 557616000 |
| Tuesday, January 1, 2019 | 10615000000 | 658498000 |
| Wednesday, January 1, 2020 | 8955000000 | 770456000 |
| Friday, January 1, 2021 | 9634000000 | 840100000 |
| Saturday, January 1, 2022 | 10042000000 | 944700000 |
| Sunday, January 1, 2023 | 10504000000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have fluctuated, peaking in 2014 and 2019, with a notable dip in 2020. This reflects a strategic shift, possibly influenced by global events and internal restructuring. In contrast, Vertex Pharmaceuticals has demonstrated a consistent upward trajectory, with expenses growing by approximately 272% over the same period. This growth underscores Vertex's aggressive expansion and investment in its operational capabilities. As we delve into these trends, it becomes evident that while Merck focuses on optimizing its existing operations, Vertex is in a phase of rapid growth and development.
Novo Nordisk A/S or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Vertex Pharmaceuticals Incorporated vs Evotec SE: SG&A Expense Trends